• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

The Manufacturing Make vs. Buy Decision for Cell and Gene Therapies: Implications for Overcoming Manufacturing Bottlenecks and Challenges

Tuesday, June 04, 2024
BioProcess Theater Session
BioProcess Theater
This panel discussion will cover considerations for manufacturing make vs. buy decisions (internal vs. outsourced manufacturing) for cell and gene therapies. Panelists will consist of executives from companies responsible for manufacturing these innovative therapies. Cell and gene therapy products present significant manufacturing challenges (cost, complexity, quality, lead times) that can be bottlenecks in the overall development timeline; the decision to outsource manufacturing vs. bringing manufacturing in-house impacts these challenges significantly and in diverse ways. The financial implications of the make vs. buy decision, and the timing of that decision may be critical and present trade-offs for achieving critical company milestones and maintaining adequate funding for early development activities. Attendees will hear the perspectives from different companies that have wrestled with this decision and will gain a deeper appreciation for the considerations involved.
Moderator
Stephen Orosz
Managing Director
BDO
Speakers
Adam Haskett
Senior Director (Head of) External Manufacturing
Cargo Therapeutics
David Fontana, PhD
Chief Operating and Chief Business Officer
Umoja Biopharma
Heikki Jouttijärvi
Senior Vice President, Manufacturing and Supply Chain Management
Adverum Biotechnologies, Inc.
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS